AI Article Synopsis
Article Abstract
Purpose: To present a case of struma ovarii with a typical features and synchronous primary thyroid carcinoma and review the available literature to guide diagnosis and management of these tumors.
Methods: We present a case from our hospital of a 55-year-old woman who had an adnexal mass with features concerning for papillary thyroid carcinoma and was ultimately determined to be struma ovarii with atypical features. Subsequent thyroid imaging and biopsy revealed a primary cervical thyroid carcinoma. We performed a PubMed search of published English language articles using the search terms "malignant struma ovarii," "metastatic struma ovarii," "struma ovarii with malignant transformation," "struma ovarii papillary thyroid carcinoma," "struma ovarii follicular thyroid carcinoma," and "struma ovarii with concurrent primary thyroid carcinoma."
Results: Literature review included 104 studies with a total of 195 patient cases. The average age at presentation was 44.9 years. 25.1% of patients had metastatic disease at presentation, and 6.2% had synchronous primary carcinomas; all of which were located in the thyroid.
Conclusions: Thyroid carcinoma arising in struma ovarii or mature cystic teratoma should prompt clinical evaluation and imaging of the thyroid given the possibility of synchronous primaries, metastases, and recurrence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00404-019-05329-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic Value of Nuclear Hybrid Imaging in Malignant Struma Ovarii: A Systematic Review of Case Reports.
Diagnostics (Basel)
November 2024
Faculty of Medicine, Department of Medical Imaging and Nuclear Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8 V. Babeș St., 400006 Cluj-Napoca, Romania.
Background: Struma ovarii is a rare tumor, a type of ovarian mature teratoma consisting over 50% of its mass in thyroid ectopic tissue; 5% to 10% of cases, as described in the literature, are malignant and well known as malignant struma ovarii or thyroid cancer from struma ovarii. Due to the limited number of malignant struma ovarii cases, the diagnostic and therapeutic approach of malignant struma ovarii lacks in standardization.
Methods: We performed a comprehensive search on the English language PubMed and Google Scholar.
Presentation and Management of Highly Differentiated Follicular Carcinoma of Ovarian Origin With Gene Variants.
JCEM Case Rep
December 2024
Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Struma ovarii (SO) is a rare subtype of ovarian teratoma composed of more than 50% thyroid tissue. Extraovarian spread of SO, called peritoneal strumosis, was previously considered benign given the lack of histological malignant features. However, the 2020 World Health Organization Classification of Female Genital Tumors reclassified peritoneal strumosis as highly differentiated follicular carcinoma of ovarian origin (HDFCO), highlighting its low-grade malignant potential.
View Article and Find Full Text PDFDisease management of malignant struma ovarii.
Hell J Nucl Med
December 2024
Department of Nuclear Medicine, Qiantang Branch of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Article Synopsis
- - Malignant struma ovarii (MSO) is a rare type of ovarian goiter that meets criteria for malignant thyroid tumors and can show invasive spread, with serum thyroglobulin (Tg) levels helping to differentiate it from other ovarian cancers.
- - A case study is presented involving a 54-year-old woman with abdominal pain, diagnosed post-surgery with highly differentiated follicular thyroid carcinoma originating from both ovaries, which had spread to other areas.
- - After undergoing total thyroidectomy and iodine-131 treatment, her follow-up after one year showed no significant abnormalities, highlighting the need for further discussion on clinical management and monitoring of Tg levels in MSO cases.
Malignant struma ovarii in pregnancy: A case report.
Gynecol Oncol Rep
December 2024
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, McMaster University, 699 Concession Street, Hamilton, Ontario L8V 5C2, Canada.
Article Synopsis
- * A 27-year-old pregnant patient was diagnosed with malignant struma ovarii after emergency surgery for ovarian torsion revealed a 3 cm tumor, initially monitored during pregnancy due to the lack of high-risk features.
- * After giving birth, the patient had a recurrence treated with extensive surgeries and radioactive iodine therapy, and she remained disease-free three years post-diagnosis, highlighting the need for personalized treatment approaches for MSO.
Prognostic significance of surgically treated malignant struma ovarii with or without adjuvant thyroid-related therapy: A systematic review and meta-analysis.
World J Surg
November 2024
Department of Endocrine Surgery, Morriston Hospital, Swansea, UK.
Article Synopsis
- The study aims to evaluate long-term survival rates and the effects of thyroid-related treatments in patients with malignant struma ovarii (MSO) after surgical treatment.
- A systematic review was conducted, analyzing 376 patients from both case reports and case series, with a primary focus on overall survival (OS) outcomes using statistical methods.
- Results indicated a high OS rate (91% at 10 years, 87% at 20 years) regardless of the type of thyroid-related therapy received, suggesting these treatments may not significantly improve survival and could be considered excessive.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!